Synthetic drugs activating PPARα and PPARγ are in clinical use: the former typified by fibrates, are used to treat dyslipidemia, while the latter include glitazones that act as insulin sensitizers in type 2 diabetes mellitus [3]. This evidence concerns the gene PPARA and metabolic syndrome.